Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits and risks of HSCT for patients with MDS, with the timing of transplantation during the disease course being a crucial question. Recently the integration of genomic screening (by Molecular International Prognostic Scoring System, IPSS-M) into patient’s assessment has resulted into a significant improvement in predicting clinical outcomes with respect to the conventional prognostic score (Revised IPSS, IPSS-R), including better stratification of post-HSCT outcome.
Here, we aimed to develop and validate a Decision Support System to define the optimal timing of HSCT in MDS patients based on clinical and genomic information as provided by IPSS-M vs conventional IPSS-R.